{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:47Z","timestamp":1792093787744,"version":"4.4.0"},"reference-count":59,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"2022 Arrigo Recordati Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The prompt control of acromegaly is a primary treatment aim for reducing related disease morbidity and mortality. First-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of medical therapies. A non-negligible number of patients do not respond to this treatment. Several predictors of fg-SRL response were identified, but a comprehensive prognostic model is lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to design a prognostic model based on clinical and biochemical parameters, and pathological features, including data on immune tumor microenvironment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, monocenter, cohort study was performed on 67 medically na\u00efve patients with acromegaly. Fifteen clinical, pathological, and radiological features were collected and analyzed as independent risk factors of fg-SRLs response, using univariable and multivariable logistic regression analyses. A stepwise selection method was applied to identify the final regression model. A nomogram was then obtained.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-seven patients were fg-SRLs responders. An increased risk to poor response to fg-SRLs were observed in somatotropinomas with absent\/cytoplasmatic SSTR2 expression (OR 5.493 95% CI 1.19-25.16, P = .028), with low CD68+\/CD8+ ratio (OR 1.162, 95% CI 1.01-1.33, P = .032). Radical surgical resection was associated with a low risk of poor fg-SRLs response (OR 0.106, 95% CI 0.025-0.447 P = .002). The nomogram obtained from the stepwise regression model was based on the CD68+\/CD8+ ratio, SSTR2 score, and the persistence of postsurgery residual tumor and was able to predict the response to fg-SRLs with good accuracy (area under the curve 0.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although our predictive model should be validated in prospective studies, our data suggest that this nomogram may represent an easy to use tool for predicting the fg-SRL outcome early.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad673","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T18:24:39Z","timestamp":1700245479000},"page":"1341-1350","source":"Crossref","is-referenced-by-count":11,"title":["The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[{"name":"UOC Endocrinology and Diabetology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Moroni","sequence":"additional","affiliation":[{"name":"Independent Researcher, PhD in Statistics, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-2045","authenticated-orcid":false,"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[{"name":"UOC Endocrinology and Diabetology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Angelini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gessi","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health Sciences and Public Health, Anatomic Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liverana","family":"Lauretti","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Calandrelli","sequence":"additional","affiliation":[{"name":"UOSD Neuroradiologia Diagnostica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del S. Cuore , Largo A. Gemelli, 8, 00168 Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tartaglione","sequence":"additional","affiliation":[{"name":"UOSD Neuroradiologia Diagnostica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del S. Cuore , Largo A. Gemelli, 8, 00168 Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Carlino","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health Sciences and Public Health, Anatomic Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gaudino","sequence":"additional","affiliation":[{"name":"UOSD Neuroradiologia Diagnostica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del S. Cuore , Largo A. Gemelli, 8, 00168 Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-4404","authenticated-orcid":false,"given":"Guido","family":"Rindi","sequence":"additional","affiliation":[{"name":"Department of Woman and Child Health Sciences and Public Health, Anatomic Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[{"name":"UOC Endocrinology and Diabetology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-6865","authenticated-orcid":false,"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[{"name":"UOC Endocrinology and Diabetology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[{"name":"UOC Endocrinology and Diabetology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli, 00168 Roma , Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , Largo A. Gemelli, 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"1","key":"2024041923063598300_dgad673-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2024041923063598300_dgad673-B2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024041923063598300_dgad673-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2022","journal-title":"J Clin Med"},{"key":"2024041923063598300_dgad673-B4","doi-asserted-by":"crossref","first-page":"646210","DOI":"10.3389\/fendo.2021.646210","article-title":"Epithelial\u2013mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly","volume":"12","author":"Gil","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024041923063598300_dgad673-B5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fendo.2015.00187","article-title":"Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement","volume":"6","author":"Peverelli","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2024041923063598300_dgad673-B6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11154-022-09782-1","article-title":"The immune microenviroment in somatotropinomas: from biology to personalized and target therapy","volume":"24","author":"Chiloiro","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2024041923063598300_dgad673-B7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"issue":"9","key":"2024041923063598300_dgad673-B8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2024041923063598300_dgad673-B9","doi-asserted-by":"crossref","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024041923063598300_dgad673-B10","first-page":"610","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"issue":"3","key":"2024041923063598300_dgad673-B11","first-page":"267","article-title":"Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review","volume":"17","author":"Chiloiro","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"2024041923063598300_dgad673-B12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-15-0586","article-title":"Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients","volume":"174","author":"Coli","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024041923063598300_dgad673-B13","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3171\/2019.3.JNS19367","article-title":"Challenging Knosp high-grade pituitary adenomas","volume":"132","author":"Micko","year":"2020","journal-title":"J Neurosurg"},{"key":"2024041923063598300_dgad673-B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121936"},{"issue":"10","key":"2024041923063598300_dgad673-B15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.humpath.2011.12.003","article-title":"A classification tree approach for pituitary adenomas","volume":"43","author":"Righi","year":"2012","journal-title":"Hum Pathol"},{"issue":"4","key":"2024041923063598300_dgad673-B16","doi-asserted-by":"crossref","first-page":"e13263","DOI":"10.1111\/jne.13263","article-title":"CD68+ And CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs","volume":"35","author":"Chiloiro","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2024041923063598300_dgad673-B17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","article-title":"Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours","volume":"67","author":"Iacovazzo","year":"2020","journal-title":"Endocrine"},{"issue":"10","key":"2024041923063598300_dgad673-B18","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/bjc.2013.634","article-title":"Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer","volume":"109","author":"Seo","year":"2013","journal-title":"Br J Cancer"},{"issue":"11","key":"2024041923063598300_dgad673-B19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"issue":"11","key":"2024041923063598300_dgad673-B20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2024041923063598300_dgad673-B21","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024041923063598300_dgad673-B22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12020-022-03275-6","article-title":"Trends in incidence and mortality risk for acromegaly in Norway: a cohort study","volume":"80","author":"Falch","year":"2022","journal-title":"Endocrine"},{"issue":"4","key":"2024041923063598300_dgad673-B23","first-page":"e14265","article-title":"Mortality in acromegalic patients: etiology, trends, and risk factors","volume":"13","author":"Alhawyan","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"2024041923063598300_dgad673-B24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000375163","article-title":"Treatment factors that influence mortality in acromegaly","volume":"103","author":"McCabe","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2024041923063598300_dgad673-B25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"2024041923063598300_dgad673-B26","doi-asserted-by":"crossref","first-page":"677919","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2024041923063598300_dgad673-B27","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly\u2014A prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024041923063598300_dgad673-B28","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024041923063598300_dgad673-B29","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2024041923063598300_dgad673-B30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1871530317666170609103332","article-title":"25-hydroxyvitamin D correlation with prolactin levels and adenoma size in female patients with newly diagnosed prolactin secreting adenoma","volume":"17","author":"Aboelnaga","year":"2017","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"2024041923063598300_dgad673-B31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/tropej\/50.1.37","article-title":"Serum prolactin in celiac disease","volume":"50","author":"Kapur","year":"2004","journal-title":"J Trop Pediatr"},{"issue":"1","key":"2024041923063598300_dgad673-B32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-005-5082-5","article-title":"Prolactin and autoimmunity","volume":"8","author":"De Bellis","year":"2005","journal-title":"Pituitary"},{"issue":"1","key":"2024041923063598300_dgad673-B33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13578-020-00488-y","article-title":"Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci"},{"issue":"10","key":"2024041923063598300_dgad673-B34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers11101605","article-title":"The microenvironment of pituitary tumors-biological and therapeutic implications","volume":"11","author":"Ilie","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2024041923063598300_dgad673-B35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","article-title":"The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications","volume":"25","author":"Marques","year":"2022","journal-title":"Pituitary"},{"issue":"3","key":"2024041923063598300_dgad673-B36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr Pathol"},{"issue":"5","key":"2024041923063598300_dgad673-B37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/jcm8050695","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"2024041923063598300_dgad673-B38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12094-022-02945-1","article-title":"Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial","volume":"25","author":"Wang","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"2024041923063598300_dgad673-B39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.hpb.2020.11.002","article-title":"The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma","volume":"23","author":"Xin","year":"2021","journal-title":"HPB (Oxford)"},{"issue":"1-2","key":"2024041923063598300_dgad673-B40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.mce.2007.10.006","article-title":"The role of somatostatin analogues in the treatment of neuroendocrine tumours","volume":"286","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2024041923063598300_dgad673-B41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2024041923063598300_dgad673-B42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024041923063598300_dgad673-B43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11102-018-0876-4","article-title":"Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1\u20135 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues","volume":"21","author":"Ozkaya","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"2024041923063598300_dgad673-B44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024041923063598300_dgad673-B45","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2024041923063598300_dgad673-B46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2024041923063598300_dgad673-B47","doi-asserted-by":"crossref","first-page":"9606985","DOI":"10.1155\/2017\/9606985","article-title":"Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"4","key":"2024041923063598300_dgad673-B48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"},{"issue":"2","key":"2024041923063598300_dgad673-B49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024041923063598300_dgad673-B50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"issue":"24","key":"2024041923063598300_dgad673-B51","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2024041923063598300_dgad673-B52","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"2024041923063598300_dgad673-B53","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"2024041923063598300_dgad673-B54","doi-asserted-by":"crossref","first-page":"101684","DOI":"10.1016\/j.beem.2022.101684","article-title":"Second line treatment of acromegaly: pasireotide or pegvisomant?","volume":"36","author":"Chiloiro","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2024041923063598300_dgad673-B55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","article-title":"Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly","volume":"78","author":"Chiloiro","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"2024041923063598300_dgad673-B56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-9966-32-40","article-title":"Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes","volume":"32","author":"Bianchi","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2024041923063598300_dgad673-B57","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"6","key":"2024041923063598300_dgad673-B58","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"key":"2024041923063598300_dgad673-B59","doi-asserted-by":"crossref","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad673\/53974985\/dgad673.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/1341\/57285747\/dgad673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/1341\/57285747\/dgad673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T23:08:18Z","timestamp":1713568098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/5\/1341\/7425418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,17]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad673","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,11,17]]}}}